Abstract
Purpose
To analyse the incidence and management of emphysematous pyelonephritis (EPN) in North West London and examine factors that influence immediate and 6-month outcomes with the aim of guiding future management.
Methods
This work analyses EPN cases from the London North West Healthcare NHS Trust from October 2006 to July 2015 (population ≈ 850,000). Diagnosis and stage were confirmed by computed tomography (CT). Demographic, clinical, biochemical and microbiological characteristics were assessed. Treatment modalities were medical management, minimally invasive management (MIM) and surgical. Immediate and 6-month outcomes were analysed.
Results
Thirteen cases were identified (f = 8, m = 5) from 5525 CT scans. EPN occurred in patients with diabetes mellitus (n = 11, 84.6%), hypertension (n = 10, 76.9%) or urinary tract calculi (n = 7, 53.85%). Unilateral EPN occurred predominantly (n = 11, 84.6%); 46.1% (n = 6) were class 1 or 2 and 53.8% (n = 7) class 3 or 4. Escherichia coli was most commonly cultured (n = 5, 38.46%). All patients received antibiotics, and ten cases required MIM. Two patients had a delayed nephrectomy, both survived. Mortality was 15.4% (n = 2, grade 1 and 3a), both died acutely post-MIM, neither underwent emergency nephrectomy. At 6 months, eight patients had ongoing renal impairment. No specific poor prognostic factors were identifiable.
Conclusions
Patients with low-grade EPN may also have a high mortality rate. In the two cases who died, earlier consideration for nephrectomy may have been prudent. It may be beneficial to have a low threshold for prompt emergency nephrectomy in severe cases and where MIM treatment has failed. We suggest a management algorithm to guide clinicians and minimise mortality.
Similar content being viewed by others
References
Huang JJ, Tseng CC (2000) Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 160(6):797–805
Tang HJ, Li CM, Yen MY, Chen YS, Wann SR, Lin HH, Lee SS, Liu YC (2001) Clinical characteristics of emphysematous pyelonephritis. J Microbiol Immunol Infect 34(2):125–130
Chuang YW, Chen CH, Cheng CH, Hung SW, Yu TM, Wu MJ, Shu KH (2007) Severe emphysematous pyelonephritis in a renal allograft: successful treatment with percutaneous drainage and antibiotics. Clin Nephrol 68(1):42–46
Lu YC, Hong JH, Chiang BJ, Pong YH, Hsueh PR, Huang CY, Pu YS (2016) Recommended initial antimicrobial therapy for emphysematous pyelonephritis: 51 cases and 14-year-experience of a tertiary referral center. Medicine 95(21):e3573. doi:10.1097/md.0000000000003573
Pontin AR, Barnes RD, Joffe J, Kahn D (1995) Emphysematous pyelonephritis in diabetic patients. Br J Urol 75(1):71–74. doi:10.1111/j.1464-410X.1995.tb07237.x
Turney JH (2000) Renal conservation for gas-forming infections. Lancet 355(9206):770–771. doi:10.1016/S0140-6736(99)00351-7
Kamaliah MD, Bhajan MA, Dzarr GA (2005) Emphysematous pyelonephritis caused by Candida infection. Southeast Asian J Trop Med Public Health 36(3):725–727
Wan YL, Lo SK, Bullard MJ, Chang PL, Lee TY (1998) Predictors of outcome in emphysematous pyelonephritis. J Urol 159(2):369–373
Uruc F, Yuksel OH, Sahin A, Urkmez A, Yildirim C, Verit A (2015) Emphysematous pyelonephritis: our experience in managing these cases. Can Urol Assoc J 9(7–8):E480–E483. doi:10.5489/cuaj.2828
Aboumarzouk OM, Hughes O, Narahari K, Coulthard R, Kynaston H, Chlosta P, Somani B (2014) Emphysematous pyelonephritis: time for a management plan with an evidence-based approach. Arab J Urol 12(2):106–115. doi:10.1016/j.aju.2013.09.005
Nana GR, Brodie A, Akhter W, Karim O, Motiwala H (2015) Nephroureterectomy for emphysematous pyelonephritis: an aggressive approach is sometimes necessary. A case report and literature review. Int J Surg Case Rep 10:179–182. doi:10.1016/j.ijscr.2015.03.051
Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N’Dow J (2008) Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol 179(5):1844–1849. doi:10.1016/j.juro.2008.01.019
Kapoor R, Muruganandham K, Gulia AK, Singla M, Agrawal S, Mandhani A, Ansari MS, Srivastava A (2010) Predictive factors for mortality and need for nephrectomy in patients with emphysematous pyelonephritis. BJU Int 105(7):986–989. doi:10.1111/j.1464-410X.2009.08930.x
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655
Dhillon RH, Clark J (2012) ESBLs: a clear and present danger? Crit Care Res Pract 2012:625170. doi:10.1155/2012/625170
Sharma M, Pathak S, Srivastava P (2013) Prevalence and antibiogram of extended spectrum β-lactamase (ESBL) producing gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res 7(10):2173–2177. doi:10.7860/JCDR/2013/6460.3462
Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B (2016) Prevalence of ESBL in Escherichia coli isolates among ICU patients in a tertiary care hospital. J Clin Diagn Res 10(9):DC19–DC22. doi:10.7860/JCDR/2016/21260.8544
Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA (2015) Antibiotic resistance and extended spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci 22(1):90–101. doi:10.1016/j.sjbs.2014.08.002
Gopal Rao G, Batura D, Batura N, Nielsen PB (2015) Key demographic characteristics of patients with bacteriuria due to extended spectrum beta-lactamase (ESBL)-producing enterobacteriaceae in a multiethnic community, in North West London. Infect Dis (Lond) 47(10):719–724. doi:10.3109/23744235.2015.1055588
Survey AP London’s population by country of birth. http://www.londonspovertyprofile.org.uk/indicators/topics/londons-geography-population/londons-population-by-country-of-birth/. Accessed 13 June 2017
Sokhal AK, Kumar M, Purkait B, Jhanwar A, Singh K, Bansal A, Sankhwar S (2017) Emphysematous pyelonephritis: changing trend of clinical spectrum, pathogenesis, management and outcome. Turk J Urol 43(2):202–209. doi:10.5152/tud.2016.14227
Olvera-Posada D, Armengod-Fischer G, Vazquez-Lavista LG, Maldonado-Avila M, Rosas-Nava E, Manzanilla-Garcia H, Castillejos-Molina RA, Mendez-Probst CE, Sotomayor M, Feria-Bernal G, Rodriguez-Covarrubias F (2014) Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology 83(6):1280–1284. doi:10.1016/j.urology.2014.02.010
Khaira A, Gupta A, Rana DS, Gupta A, Bhalla A, Khullar D (2009) Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis. Int Urol Nephrol 41(4):959–966. doi:10.1007/s11255-009-9552-y
Acknowledgements
We would like to thank Dipesh Hirani and Neil Barron for data searches in the radiology reporting system (Spectra PACS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Neither author has any conflicts of interest to declare.
Ethical approval
This article does not contain any studies with animals performed by any of the authors. This study was carried out in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent
This was a retrospective study with anonymised data, not requiring informed consent.
Rights and permissions
About this article
Cite this article
Boakes, E., Batura, D. Deriving a management algorithm for emphysematous pyelonephritis: Can we rely on minimally invasive strategies or should we be opting for earlier nephrectomy?. Int Urol Nephrol 49, 2127–2136 (2017). https://doi.org/10.1007/s11255-017-1706-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-017-1706-8